Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia

Journal of Pharmaceutical Sciences

Volumn 101, Issue 8, 2012, Pages 2821-2832

  Azcona, Luis ^a   Antonio J , López Farré ^a   Petra Jiménez, Mateos Cáceres ^a   Antonio, Segura ^b   Pablo, Rodríguez ^a   Javier, Modrego ^a   José J , Zamorano León ^a   Carlos, Macaya ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Health Sciences Institute   (Spain)

Author keywords

Drug effects; Drug interaction; Mass spectrometry; Metabolism; Proteomics

Indexed keywords

ACETYLSALICYLIC ACID; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; ORAL ANTIDIABETIC AGENT; PROTEIN; PROTEIN DISULFIDE ISOMERASE; RAB PROTEIN; SEROTRANSFERRIN; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

AGED; ARTICLE; DIABETIC PATIENT; DRUG EFFECT; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOSIS; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 84862878891     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23201     Document Type: Article

References (33)

1. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A. 2007. Impact of platelet reactivity on cardiovascular outcomes in patients with type-2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50:1541-1547.
2. Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. 2010. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 7:251-259.
3. Colwell JA, Nesto RW. 2003. The platelet in diabetes: Focus on prevention of ischemic events. Diabetes Care 26:2181-2188.
4. Tuttle HA, Davis-Gorman G, Goldman S, Copeland JG, McDonagh PF. 2004. Proinflammatory cytokines are increased in type-2 diabetic women with cardiovascular disease. J Diabetes Complications 18:343-351.
5. Ross R. 1999. Atherosclerosis: An inflammatory disease. N Engl J Med 340:115-26.
6. Granger DN, Vowinkel T, Petnehazy T. 2004. Modulation of the inflammatory response in cardiovascular disease. Hypertension 43:924-31.
7. Antithrombotic Trialists' Collaboration. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86.
8. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. 2008. Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis. BJM 336:195-198.
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C. 2006. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55:780-784.
10. Molero L, López-Farré A, Mateos-Cáceres PJ, Fernández-Sánchez R, Luisa Maestro M, Silva J, Rodríguez E, Macaya C. 2005. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol 146:419-424.
11. Doery JCG, Hirsh J, Cooper I. 1970. Energy metabolism in human platelets: Interrelationship between glycolysis and oxidative metabolism. Blood 36:159-168.
12. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. 2004. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 34:205-209.
13. Mateos-Cáceres PJ, García-Méndez A, López Farré A, Macaya C, Núñez A, Gómez J, Alonso-Orgaz S, Carrasco C, Burgos ME, de Andrés R, Granizo JJ, Farré J, Rico LA. 2004. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 44:1578-1583.
14. López-Farré AJ, Mateos-Cáceres PJ, Sacristán D, Azcona L, Bernardo E, de Prada TP, Alonso-Orgaz S, Fernández-Arquero M, Fernández-Ortiz A, Macaya C. 2007. Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: A proteomic study. J Proteome Res 6:2481-2487
15. Sacristán D, Marques M, Zamorano-León JJ, Luque M, Armengol J, Del Castillo J, Martín J, Delpón E, Ramos-Mozo P, de Prada TP, Tamargo J, Barrientos A, Macaya C, López-Farré A. 2008. Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. Proteomics Clin Appl 2:1300-1312.
16. Alonso-Orgaz S, Moreno L, Macaya C, Rico L, Mateos-Cáceres PJ, Sacristán D, Pérez-Vizcaíno F, Segura A, Tamargo J, López-Farré A. 2006. Proteomic study of plasma from moderate hypercholesterolemic patients. J Proteome Res 5:2301-2308.
17. Mateos-Cáceres PJ, Macaya C, Azcona L, Modrego J, Mahillo E, Bernardo E, Fernández-Ortiz A, López-Farré AJ. 2010. Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb Haemost 103:60-170.
18. Marques M, Sacristán D, Mateos-Cáceres PJ, Herrero J, Arribas MJ, González-Armengol JJ, Villegas A, Macaya C, Barrientos A, López-Farré AJ. 2010. Different protein expression in normal and dysfunctional platelets from uremic patients. J Nephrol 23:90-101.
19. Andrews RK, Fox JE. 1991. Interaction of purified actin-binding protein with the platelet membrane glycoprotein Ib-IX complex. J Biol Chem 266:7144-7147.
20. Warshaw AL, Laster L, Shulman NR. 1966. The stimulation by thrombin of glucose oxidation in human platelets. J Clin Invest 45:193-194.
21. Leoncini G, Maresca M, Balestrero F, Polvani C, Armani U, Piana A. 1987. Platelet glucose metabolism in type I diabetic subjects. Eur J Haematol 39:166-171.
22. Jennings PE, McLaren M, Scott NA, Saniabadi AR, Belch JJ. 1991. The relationship of oxidative stress to thrombotic tendency in type 1 diabetic patients with retinopathy. Diabet Med 8:860-865.
23. Kanko M, Maral H, Akbas MH, Ozden M, Bulbul S, Omay O, Yavuz S, Berki KT. 2005. Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. Tohoku J Exp Med 205:133-139.
24. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. 1997. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional risk factors. J Am Soc Nephrol 8:475-486.
25. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Böger R, Baldus S. 2006. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: Evidence for antioxidant and anti-inflammatory effects. Arterioscler Thromb Vasc Biol 26:1648-1652.
26. Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Guzman LA, Bass TA. 2008. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study. Eur Heart J 29:2202-2211.
27. Douglas JS Jr., Holmes DR Jr., Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS. 2005. Cilostazol for Restenosis Trial (CREST) Investigators, Coronary stent restenosis in patients treated with cilostazol. Circulation 112:2826-2832.
28. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, Plow E, Topol EJ. 2004. Effect of clopidogrel pre-treatment on inflammatory marker expression in patients undergoing percutaneous intervention. Am J Cardiol 93:679-684.
29. Reaume KT, Regal RE, Dorsch MP. 2008. Indications for dual antiplatelet therapy with aspirin and clopidogrel: Evidence-based recommendations for use. Ann Pharmacother 42:550-557.
30. Sullivan J, Amarshi N. 2008. Dual antiplatelet therapy with clopidogrel and aspirin. Am J Health Syst Pharm 65:1134-1143.
31. Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, Herdeg C, May AE, Gawaz M. 2007. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30:372-374.
32. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. 2007. CHARISMA Investigators, patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49:1982-1988.
33. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A. 2007. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55:1139-1146.